Atossa Therapeutics, Inc.
$1.96
The Read: Atossa Therapeutics' stock showed limited gains around Q1 2026 earnings despite meeting EPS estimates and prior positive trial news, but concerns over cash runway and burn rate led to a steady decline, and later ASCO updates lacking new clinical data kept the stock flat.
Price
Overlays
Panel
ATOS
Hover to view data
No Data